Response of Factor VIII and IX-Deficient Blood to Wild Type and High Membrane Affinity Mutant Factor VIIa in an In Vitro Whole Blood Clotting Assay: Possible Correlation to Clinical Outcome

Summary

A modified form of the activated whole blood clotting time was used to evaluate response of blood from hemophilia patients to factor VIIa. Repeated assays of individuals over a one-year period showed consistency for each individual and significant difference between individuals. Four hemophilia patients with inhibitors gave low response to factor VIIa in the assay and were characterized as low or moderate clinical responders to factor VIIa therapy. Another four patients with moderate to good clinical responsiveness to factor VIIa therapy showed a strong response to factor VIIa in the assay. A factor VIIa mutant with enhanced membrane affinity showed 10 to 13-fold higher activity than wild type factor VIIa. The results may justify larger studies to determine the utility of this assay for evaluation of patient responsiveness and to set factor VIIa therapy levels.

Keywords

Factor VIIa - hemophilia

• References

• 1 Lusher JM, Ingerslev J, Roberts HR, Hedner U. Clinical experience with recombinant factor VIIa. Blood Coagul Fibrinolysis 1998; 09: 119-28.
• 2 Aledort LM. Recombinant factor VIIa is a pan-hemostatic agent?. Thromb Haemost 2000; 83: 637-8.
• 3 Key NS, Aledort LM, Beardsley D, Cooper HA, Davignon G, Ewenstein BM, Gilchrist GS, Gill JC, Glader B, Hoots WK, Kisker CT, Lusher JM, Rosenfield CG, Shapiro AD, Smith H, Taft E. Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost 1998; 80: 912-8.
• 4 Monroe DM, Hoffman M, Oliver JA, Roberts HR. A possible mechanism of action of activated factor VII independent of tissue factor. Blood 1998; 09 (Suppl. 01) S15-S20.
• 5 Shah AM, Kisiel W, Foster DC, Nelsestuen GL. Manipulation of the membrane binding site of vitamin K-dependent proteins: Enhanced biological function of human factor VII. Proc Natl Acad Sci 1998; 95: 4229-34.
• 6 Nelsestuen GL, Stone M, Martinez MB, Harvey SB, Foster DC, Kisiel W. Elevated function of blood clotting factor VIIa mutants that have enhanced affinity for membranes. Behavior in a diffusion-limited reaction. J Biol Chem 2001; 276 (43) 39825-31.
• 7 Giesen PL, Rauch U, Bohrmann B, Kling D, Rouque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Blood-borne tissue factor: another view of thrombosis. Proc Natl Acad Sci 1999; 96: 2311-5.
• 8 Key NS, Slungaard A, Dandelet L, Nelson SC, Moertel C, Styles LA, Kuypers FA, Bach RR. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood 1998; 91: 4216-23.
• 9 Sumner WT, Monroe DM, Hoffman M. Variability in platelet procoagulant activity in healthy volunteers. Thromb Res 1996; 81: 533-43.
• 10 Edson JR, Krivit W, White JG. Kaolin partial thromboplastin time: ligh levels of procoagulants producing short clotting times masking deficiencies of other procoagulants or low concentrations of anticoagulants. J Lab Clin Med 1967; 701: 463-7.
• 11 Carter AJ, Hicks K, Heldman AW, Resar JR, Laird JR, Coombs V, Brinker JA, Blumenthal RS. Clinical evaluation of a microsample coagulation analyzer, and comparison with existing techniques. Cathet Cardiovasc Diagn 1996; 39: 97-102.
• 12 Margolis J. An improved procedure for accurate assays of factor VIII. Pathology 1979; 11: 149-59.
• 13 Kessler CM, Bernstein Z, Ghesani S, Shamsipour Z, Frances C, Zucker ML, LaDuca FM. Bedside measurement of factor VIII:C activity in individuals with hemophilia A. Am J Hematol 1996; 51: 181-5.
• 14 Key NS, Christie B, Henderson N, Nelsestuen GL. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy: Evaluation by an in vitro test. Thromb Haemost 2002; 88: 60-5.